BSX: מחיר למכירות Boston Scientific Corp

Boston Scientific is expanding its presence in the cardiology and endoscopy segments driven by an aging population. The P/S ratio history confirms this trend, with the parameter stabilizing at 3.00. Growth is supported by a wide range of implantable devices for global clinics. High plant utilization and the implementation of automated product quality control ensure stability.

Fundamental asset selection requires comparing the market value of a business with actual sales volume to avoid overpaying for inflated expectations. This ratio measures the cost of each unit of revenue, which is critical for Boston Scientific (BSX) amid component logistics disruptions and sanction restrictions; therefore, the current P/S valuation clearly reflects the impact of operational risks on capitalization.